Journal
CONTRAST MEDIA & MOLECULAR IMAGING
Volume 3, Issue 1, Pages 2-8Publisher
JOHN WILEY & SONS LTD
DOI: 10.1002/cmmi.223
Keywords
contrast agent; computed tomography; magnetic resonance; Gd-based agent; dendrimer
Funding
- NATIONAL CANCER INSTITUTE [ZIASC006353, ZIASC010051] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS003051] Funding Source: NIH RePORTER
- Intramural NIH HHS [Z01 SC010051-11] Funding Source: Medline
- NCI NIH HHS [N01CO12400] Funding Source: Medline
Ask authors/readers for more resources
The feasibility of using Gd dendrimer-based macromolecules (Gd-G8 dendrimer) as a dual CT and MR contrast agent for monitoring convection-enhanced delivery of therapy in the brain is evaluated both in vitro and in vivo with optimal dosing established. In vitro CT attenuation values of the Gd-based agents (similar to 6.0 HU mm(-1)) were similar to 1.6 times greater than iodine-based agents and the attenuation of the Gd-DTPA was comparable to Gd-G8 dendrimer. Visible enhancement was observed on both CT and MR using Gd-G8 dendrimer over a range of 23-78 mm; however, a concentration of at least 47 mm in Gd was required for adequate delineation of the injection site on both CT and MR. MR offers greater sensitivity than CT in estimating the volume of distribution (V-d) and effectively quantified the agent's concentration and diffusion using T, mapping at much lower concentrations of Gd (< 10 mm in [Gd]). Copyright (c) 2008 John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available